{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1390282679754528512.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.5649/jjphcs.32.314"}},{"identifier":{"@type":"NDL_BIB_ID","@value":"10558713"}},{"identifier":{"@type":"NAID","@value":"110004689798"}},{"identifier":{"@type":"URI","@value":"http://id.ndl.go.jp/digimeta/10558713"}},{"identifier":{"@type":"URI","@value":"https://dl.ndl.go.jp/pid/10558713"}},{"identifier":{"@type":"URI","@value":"http://dl.ndl.go.jp/info:ndljp/pid/10558713"}},{"identifier":{"@type":"URI","@value":"https://search.jamas.or.jp/link/ui/2006221461"}}],"dc:title":[{"@language":"en","@value":"Blood Purification Methods Prove to be Effective in Emergency Treatment in a Case of Delayed Excretion of Methotrexate"},{"@language":"ja","@value":"Ｍｅｔｈｏｔｒｅｘａｔｅ排せつ遅延に対し血液浄化法が有用だった１例―救援療法としての血液浄化法の評価―"},{"@value":"Methotrexate排滑遅延に対し血液浄化法が有用だった1例 : 救援療法としての血液浄化法の評価"}],"dcterms:alternative":[{"@language":"ja","@value":"―救援療法としての血液浄化法の評価―"}],"dc:language":"ja","description":[{"type":"abstract","notation":[{"@language":"en","@value":"The large dose administration of the carcinostatic agent methotrexate (MTX), a folic acid antagonist, is effective in treating osteosarcoma but its use is often accompanied by critical adverse effects. Forty-eight hours after administering MTX to a 9-year old female osteosarcoma patient the blood concentration of MTX was 283μM, approximately 280 times higher than the reference level, due to delayed excretion. However, the full amount of calcium folinate (Leucovorin<sup>®</sup> : LV) needed to antagonize such a high concentration of MTX in the blood was not available since it is produced in very small amounts. Therefore, we recommended blood purification methods such as hemodialysis plus hemoperfusion (HD+HP) and plasma exchange (PE) to reduce the high MTX concentration. HD+HP and PE achieved decreases in the MTX level of 76% and 34%, respectively. Though clinical tests implied hypofunction of the kidney and liver and myelosuppression, serious adverse effects such as decrease in urine volume, jaundice, and infection were not observed.<br>Thus, the blood purification methods of HD+HP and PE were effective in emergency treatment for a patient with delayed excretion of MTX."}],"abstractLicenseFlag":"disallow"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1410282763091933445","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000006090893"}],"foaf:name":[{"@language":"en","@value":"Kimura Naomi"},{"@language":"ja","@value":"木村 尚美"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Pharmacy, Hokkaido Cancer Center, National Hospital Organization"},{"@language":"ja","@value":"独立行政法人国立病院機構北海道がんセンター薬剤科"}]},{"@id":"https://cir.nii.ac.jp/crid/1410845713043585537","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000006090894"}],"foaf:name":[{"@language":"en","@value":"Tanaka Hiroyuki"},{"@language":"ja","@value":"田中 寛之"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Pharmacy, Hokkaido Cancer Center, National Hospital Organization"},{"@language":"ja","@value":"独立行政法人国立病院機構北海道がんセンター薬剤科"}]},{"@id":"https://cir.nii.ac.jp/crid/1410853646341935619","@type":"Researcher","foaf:name":[{"@language":"en","@value":"Kawaguchi Hiroyuki"},{"@language":"ja","@value":"川口 啓之"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Pharmacy, Hokkaido Cancer Center, National Hospital Organization"},{"@language":"ja","@value":"独立行政法人国立病院機構北海道がんセンター薬剤科"}]},{"@id":"https://cir.nii.ac.jp/crid/1410853646341935488","@type":"Researcher","foaf:name":[{"@language":"en","@value":"Eguchi Hisae"},{"@language":"ja","@value":"江口 久恵"}],"jpcoar:affiliationName":[{"@language":"ja","@value":"独立行政法人国立病院機構北海道がんセンター薬剤科"},{"@language":"en","@value":"Department of Pharmacy, Hokkaido Cancer Center, National Hospital Organization"}]},{"@id":"https://cir.nii.ac.jp/crid/1410001288109047936","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000002864893"}],"foaf:name":[{"@language":"en","@value":"Endo Kazushi"},{"@language":"ja","@value":"遠藤 一司"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Pharmacy, Hokkaido Cancer Center, National Hospital Organization"},{"@language":"ja","@value":"独立行政法人国立病院機構北海道がんセンター薬剤科"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"1346342X"},{"@type":"LISSN","@value":"1346342X"},{"@type":"EISSN","@value":"18821499"},{"@type":"NCID","@value":"AA11527197"}],"prism:publicationName":[{"@language":"en","@value":"Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)"},{"@language":"ja","@value":"医療薬学"},{"@language":"en","@value":"Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)"},{"@language":"en","@value":"JJPHCS"},{"@language":"en","@value":"Jpn. J. Pharm. Health Care Sci."},{"@language":"ja","@value":"医療薬学"}],"dc:publisher":[{"@language":"en","@value":"Japanese Society of Pharmaceutical Health Care and Sciences"},{"@language":"ja","@value":"一般社団法人日本医療薬学会"}],"prism:publicationDate":"2006","prism:volume":"32","prism:number":"4","prism:startingPage":"314","prism:endingPage":"319"},"reviewed":"false","url":[{"@id":"http://id.ndl.go.jp/digimeta/10558713"},{"@id":"https://dl.ndl.go.jp/pid/10558713"},{"@id":"http://dl.ndl.go.jp/info:ndljp/pid/10558713"},{"@id":"https://search.jamas.or.jp/link/ui/2006221461"}],"availableAt":"2006","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=methotrexate%20(MTX)","dc:title":"methotrexate (MTX)"},{"@id":"https://cir.nii.ac.jp/all?q=osteosarcoma","dc:title":"osteosarcoma"},{"@id":"https://cir.nii.ac.jp/all?q=high-dose%20MTX%20therapy%20(HDMTX)","dc:title":"high-dose MTX therapy (HDMTX)"},{"@id":"https://cir.nii.ac.jp/all?q=blood%20purification","dc:title":"blood purification"},{"@id":"https://cir.nii.ac.jp/all?q=hemodialysis%20and%20hemoperfusion%20(HD+HP)","dc:title":"hemodialysis and hemoperfusion (HD+HP)"},{"@id":"https://cir.nii.ac.jp/all?q=plasma%20exchange%20therapy%20(PE)","dc:title":"plasma exchange therapy (PE)"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360292619261768704","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"High dose methotrexate with leucovorin rescue"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544419513967616","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Adjuvant Methotrexate and Citrovorum-Factor Treatment of Osteogenic Sarcoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107369469885056","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The Pharmacology and Clinical Use of Methotrexate"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670318256489344","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Efficacy of high-dose methotrexate in childhood acute lymphocytic leukemia: analysis by contemporary risk classifications"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951793771624320","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate."}]},{"@id":"https://cir.nii.ac.jp/crid/1390282680011978624","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"人工肛門造設後の大量メトトレキサートにより急性腎不全をきたした1例"},{"@language":"en","@value":"Acute renal failure after high-dose methotrexate therapy in a patient with ileostomy"},{"@value":"症例報告 人工肛門造設後の大量メトトレキサートにより急性腎不全をきたした1例"},{"@language":"ja-Kana","@value":"ショウレイ ホウコク ジンコウコウモンゾウセツゴ ノ タイリョウ メトトレキサート ニ ヨリ キュウセイ ジンフゼン オ キタシタ 1レイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1570572699095846656","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@value":"High-Dose MTX療法における重篤な副作用の検討"}]},{"@id":"https://cir.nii.ac.jp/crid/1570572700551111936","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Efficacy of hghi-dose Methotrexate in childhood acute lymphocyic leukemia : Analysis by contemporary risk classifications"}]},{"@id":"https://cir.nii.ac.jp/crid/1571135650504531456","@type":"Article","relationType":["cites"]},{"@id":"https://cir.nii.ac.jp/crid/1571135650555997056","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@value":"ロイコボリン救援療法による大量メソトレキセート療法"}]},{"@id":"https://cir.nii.ac.jp/crid/1571980075434665472","@type":"Article","relationType":["cites"]},{"@id":"https://cir.nii.ac.jp/crid/1572824500364795520","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"7-Hydroxymethotrexate as a urine metabolite in human subjects and rhesus monkeys receiving high dose methotrexate"}]},{"@id":"https://cir.nii.ac.jp/crid/1572824500364797952","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"High dose Methotrexate with Leucovorin rescue"}]},{"@id":"https://cir.nii.ac.jp/crid/1572824501572357504","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@value":"骨肉腫に対する Methotraxate (MTX) 大量療法による薬物療法による薬物中毒-Leucovorin (LV) 大量療法と血液吸着法により救命し得た一例-"}]},{"@id":"https://cir.nii.ac.jp/crid/1573105974979870464","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@value":"血液浄化法が奏効したメソトレキサート中毒の1例"}]},{"@id":"https://cir.nii.ac.jp/crid/1573105975393429120","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@value":"血液透析併用療法により救命しえたメソトレキサート大量療法後急性腎不全の1例"}]},{"@id":"https://cir.nii.ac.jp/crid/1574231875248348672","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"The pharmacology and clinical use of methotrexate"}]},{"@id":"https://cir.nii.ac.jp/crid/1574231875248349824","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Aduvant methotrexate and citovrum factor treatment of osteogenic sarcoma"}]}],"dataSourceIdentifier":[{"@type":"JALC","@value":"oai:japanlinkcenter.org:0027786721"},{"@type":"NDL_SEARCH","@value":"oai:ndlsearch.ndl.go.jp:R100000039-I10558713"},{"@type":"CROSSREF","@value":"10.5649/jjphcs.32.314"},{"@type":"NDL_DC","@value":"info:ndljp/pid/10558713"},{"@type":"CIA","@value":"110004689798"}]}